scispace - formally typeset
Y

Yixin Wang

Researcher at Li Ka Shing Faculty of Medicine, University of Hong Kong

Publications -  101
Citations -  15619

Yixin Wang is an academic researcher from Li Ka Shing Faculty of Medicine, University of Hong Kong. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 38, co-authored 87 publications receiving 13630 citations. Previous affiliations of Yixin Wang include Johnson & Johnson & University of Ljubljana.

Papers
More filters
Journal ArticleDOI

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

TL;DR: The ability to identify patients who have a favourable prognosis could, after independent confirmation, allow clinicians to avoid adjuvant systemic therapy or to choose less aggressive therapeutic options.
Journal ArticleDOI

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

TL;DR: In meta-analyses involving taxane-based or anthracycline-based regimens, proportional risk reductions were little affected by age, nodal status, tumour diameter or differentiation (moderate or poor; few were well differentiated), oestrogen receptor status, or tamoxifen use.
Journal ArticleDOI

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

TL;DR: After mastectomy and axillary dissection, radiotherapy reduced both recurrence and breast cancer mortality in the women with one to three positive lymph nodes in these trials even when systemic therapy was given.
Journal ArticleDOI

Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression

TL;DR: This large-scale genomic analysis illustrates that breast cancer arising in young women is a unique biologic entity driven by unifying oncogenic signaling pathways, is characterized by less hormone sensitivity and higher HER-2/EGFR expression, and warrants further study to offer this poor-prognosis group of women better preventative and therapeutic options.